Breast Cancer Trial, Not Yet Recruiting NCT07562399 Sponsor: Dana-Farber Cancer Institute Condition: Breast Cancer
Back to Breast Cancer

Breast Cancer Trial, Not Yet Recruiting

NCT07562399
Not Yet Recruiting Not Applicable

voxsanity.com.au · Eligibility summary from public government registries · 18 August 2026 · not medical advice

Who may and may not be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who may be able to join

  • The person must be female.
  • The person must be 18 years of age or older.
  • The person must have a confirmed diagnosis of estrogen receptor (ER)-positive breast cancer, verified through laboratory testing.
  • The cancer must be confirmed, through physical examination or imaging, to be located only in the breast and nearby lymph nodes.
  • The person must be between 6 and 36 months into starting a type of hormone-blocking treatment for breast cancer (called adjuvant endocrine therapy, or AET).
  • The person must have a cellphone that can receive text messages.
  • The person must currently be receiving AET treatment at Butaro Hospital or one of its satellite clinics.

Who may not be able to join

Each point below is a reason the trial team may not be able to accept someone. It is not a list of requirements to meet.

  • People who are unwilling or unable to take part in the study.
  • People who are not able to understand the study languages, which are English or Kinyarwanda.
  • People who are not able to give their own informed consent to participate.
  • People who are not yet adults, including infants, children, and teenagers.
  • People who are currently imprisoned.
  • People who are pregnant.

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 29 July 2026
This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.

Contact this trial

Principal Investigator: Temidayo Fadelu, MD, Dana-Farber Cancer Institute

Phone: 617-632-3779

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Not Yet Recruiting
Phase
Not Applicable
Registry
ClinicalTrials.gov
Start date
20 September 2026
Est. completion
31 December 2027

Where this trial is recruiting

Rwanda 🇺🇸 United States

Primary endpoints

3-month Adherence Rate

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 29 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov